1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Metastatic Lung Cancer - Pipeline Review, H2 2013

Metastatic Lung Cancer - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 54 pages

Metastatic Lung Cancer - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Metastatic Lung Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Lung Cancer. Metastatic Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Lung Cancer.
- A review of the Metastatic Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Lung Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Lung Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Lung Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Metastatic Lung Cancer - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Lung Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Metastatic Lung Cancer 8
Metastatic Lung Cancer Therapeutics under Development by Companies 10
Metastatic Lung Cancer Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Metastatic Lung Cancer Therapeutics - Products under Development by Companies 15
Metastatic Lung Cancer Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Metastatic Lung Cancer Therapeutics Development 17
Alkermes, Inc. 17
BioLineRx, Ltd. 18
AntiCancer, Inc. 19
Vascular Biogenics Ltd. 20
Targa Therapeutics Corp. 21
Metastatic Lung Cancer - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
VB-111 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
GM.CD40L Cell Vaccine + [cyclophosphamide] + [tretinoin] - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
VEGF/rGel - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
CNVN-202 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
BL-8040 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Sticky siRNA - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Salmonella typhimurium A1-R - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
RDB-1419 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Beta-ManCer Vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
LY-364937 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Metastatic Lung Cancer Therapeutics - Drug Profile Updates 42
Metastatic Lung Cancer Therapeutics - Discontinued Products 45
Metastatic Lung Cancer Therapeutics - Dormant Products 46
Metastatic Lung Cancer - Product Development Milestones 47
Featured News and Press Releases 47
Mar 04, 2013: Starpharma's Dendrimers-based Formulation Of Doxorubicin Improves Anticancer Efficacy In Lung Metastasis Model 47
Feb 26, 2013: Pfizer's Xalkori Receives Chinese Approval For Treatment Of Non-small Cell Lung Cancer 48
Jan 18, 2013: IPAB Begins Final Hearing On Bayer's Appeal Against Natco Pharma 48
Aug 13, 2012: Health Canada Approves TARCEVA As First-Line Therapy For Treatment Of Non-Small Cell Lung Cancer 49
Jun 20, 2011: Momenta Announces Publication Of Preclinical Results Of Oncology Drug M402 In PLoS One 49
Jun 10, 2011: CureVac Presents Promising New Data For Lung Cancer Vaccine CV9201 At ASCO Conference 50
May 19, 2011: VBL Therapeutics Presents Preclinical Data For VB-111 At 14th Annual ASGCT Meeting 50
Nov 10, 2010: Silence Reports Positive Preclinical Research Findings Of Atu027 In Pulmonary Metastasis Animal Models 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54



List of Tables

Number of Products Under Development for Metastatic Lung Cancer, H2 2013 8
Products under Development for Metastatic Lung Cancer - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Alkermes, Inc., H2 2013 17
BioLineRx, Ltd., H2 2013 18
AntiCancer, Inc., H2 2013 19
Vascular Biogenics Ltd., H2 2013 20
Targa Therapeutics Corp., H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Combination Products, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 27
Metastatic Lung Cancer Therapeutics - Drug Profile Updates 42
Metastatic Lung Cancer Therapeutics - Discontinued Products 45
Metastatic Lung Cancer Therapeutics - Dormant Products 46



List of Figures

Number of Products under Development for Metastatic Lung Cancer, H2 2013 8
Products under Development for Metastatic Lung Cancer - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 22
Assessment by Combination Products, H2 2013 23
Assessment by Route of Administration, H2 2013 24
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Molecule Type, H2 2013 26
Assessment by Stage and Molecule Type, H2 2013 27



Companies Mentioned

Alkermes, Inc.
BioLineRx, Ltd.
AntiCancer, Inc.
Vascular Biogenics Ltd.
Targa Therapeutics Corp.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila ...

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline ...

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.